The Asia Pacific Antibody Drug Conjugates Market would witness market growth of 15.0% CAGR during the forecast period (2022-2028).
Cleavable linkers are one type of ADC linker that may be cleaved by environmental conditions like pH and redox potential, as well as lysosomal enzymes. G lutathione sensitive linker (SPDB), pH-sensitive linker (hydrazone), and protease-sensitive linker are the three types of cleavable linkers employed (valine citrulline). Non-cleavable linkers are made up of stable bonds that withstand proteolytic degradation and are more stable than cleavable linkers. The non-cleavable linker's method of action is based on the ADC complex's molecularity, which is followed by the lysosome's breakdown of the mAb component, resulting in the release of a cytotoxic medicine that kills tumor cells.
Antibody-drug conjugates are made up of three parts: an antibody specific for the target-related antigen, an antigen that has limited expression on normal cells, a cytotoxic agent that kills target cancer cells, and a chemical linker that connects the cytotoxic agent to the antibody. Antibody-drug conjugates have therapeutic potential but face technological and developmental obstacles. In addition, antibody-drug conjugates are the current era of medicinal agents. It combines the power of monoclonal antibodies to target specific cells with the ability of cytotoxic medicines to kill such cells.
Cancer and other non-communicable illnesses are becoming serious public health issues in India. Such diseases are caused by poor lifestyle choices, have a long latency period, and require specialized infrastructure and human resources to treat. India continues to have a heavy burden of avoidable communicable diseases, creating competition for resources. Tobacco, eating choices, poor physical activity, and alcohol intake are risk factors for the major non-communicable diseases. It opens up the possibility of implementing combined primary preventive techniques. Population-based cancer registries inside and outside the National Cancer Registry Program have produced a picture of India's cancer pattern. It has some locations that are largely not represented, but the overall pattern appears to be consistent. For instance, according to cancer registry data, over 800,000 new cancer cases will be diagnosed in India each year. At any given time, the load is probably to be three times that of the 240,000 instances. Tobacco-related malignancies account for 35 to 50 percent of all cancers in males and 17 percent of cancers in women. The malignancies could be managed to a significant extent with primary prevention.
The China market dominated the Asia Pacific Antibody Drug Conjugates Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,061 Million by 2028. The Japan market is estimated to grow at a CAGR of 14.3% during (2022 - 2028). Additionally, The India market would witness a CAGR of 15.7% during (2022 - 2028).
Based on Application, the market is segmented into Breast Cancer, Blood Cancer, Urothelial Cancer & Bladder Cancer, and Others. Based on Technology, the market is segmented into Cleavable Linker, Non-Cleavable Linker, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Antibody Drug Conjugates Market is Projected to reach USD 13.8 Billion by 2028, at a CAGR of 14.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca PLC, GlaxoSmithKline PLC, Pfizer, Inc., Astellas Pharma, Inc., Gilead Sciences, Inc., Seagen, Inc., ADC Therapeutics SA, and Daiichi Sankyo Company, Limited.
Scope of the Study
Market Segments Covered in the Report:
By Application
- Breast Cancer
- Blood Cancer
- Urothelial Cancer & Bladder Cancer
- Others
By Technology
- Cleavable Linker
- Non-Cleavable Linker
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Takeda Pharmaceutical Company Limited
- F. Hoffmann-La Roche Ltd.
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Pfizer, Inc.
- Astellas Pharma, Inc.
- Gilead Sciences, Inc.
- Seagen, Inc.
- ADC Therapeutics SA
- Daiichi Sankyo Company, Limited
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Antibody Drug Conjugates Market, by Application
1.4.2 Asia Pacific Antibody Drug Conjugates Market, by Technology
1.4.3 Asia Pacific Antibody Drug Conjugates Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition & mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, May – 2022, Mar) Leading Players
Chapter 4. Asia Pacific Antibody Drug Conjugates Market by Application
4.1 Asia Pacific Breast Cancer Market by Country
4.2 Asia Pacific Blood Cancer Market by Country
4.3 Asia Pacific Urothelial Cancer & Bladder Cancer Market by Country
4.4 Asia Pacific Others Market by Country
Chapter 5. Asia Pacific Antibody Drug Conjugates Market by Technology
5.1 Asia Pacific Cleavable Linker Market by Country
5.2 Asia Pacific Non-Cleavable Linker Market by Country
5.3 Asia Pacific Others Market by Country
Chapter 6. Asia Pacific Antibody Drug Conjugates Market by Country
6.1 China Antibody Drug Conjugates Market
6.1.1 China Antibody Drug Conjugates Market by Application
6.1.2 China Antibody Drug Conjugates Market by Technology
6.2 Japan Antibody Drug Conjugates Market
6.2.1 Japan Antibody Drug Conjugates Market by Application
6.2.2 Japan Antibody Drug Conjugates Market by Technology
6.3 India Antibody Drug Conjugates Market
6.3.1 India Antibody Drug Conjugates Market by Application
6.3.2 India Antibody Drug Conjugates Market by Technology
6.4 South Korea Antibody Drug Conjugates Market
6.4.1 South Korea Antibody Drug Conjugates Market by Application
6.4.2 South Korea Antibody Drug Conjugates Market by Technology
6.5 Singapore Antibody Drug Conjugates Market
6.5.1 Singapore Antibody Drug Conjugates Market by Application
6.5.2 Singapore Antibody Drug Conjugates Market by Technology
6.6 Malaysia Antibody Drug Conjugates Market
6.6.1 Malaysia Antibody Drug Conjugates Market by Application
6.6.2 Malaysia Antibody Drug Conjugates Market by Technology
6.7 Rest of Asia Pacific Antibody Drug Conjugates Market
6.7.1 Rest of Asia Pacific Antibody Drug Conjugates Market by Application
6.7.2 Rest of Asia Pacific Antibody Drug Conjugates Market by Technology
Chapter 7. Company Profiles
7.1 Takeda Pharmaceutical Company Limited
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expense
7.1.1 Recent strategies and developments:
7.1.1.1 Partnerships, Collaborations, and Agreements:
7.1.1.2 Acquisitions and Mergers:
7.2 F. Hoffmann-La Roche Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.3 AstraZeneca PLC
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Partnerships, Collaborations, and Agreements:
7.4 GlaxoSmithKline PLC
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.4.5.2 Approvals and Trials:
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional & Segmental Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations and Agreements:
7.6 Astellas Pharma, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.6.5.2 Approvals and Trials:
7.7 Gilead Sciences, Inc.
7.7.1 Company overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expenses
7.7.4 Recent strategies and developments:
7.7.4.1 Acquisitions and Mergers:
7.7.4.2 Partnerships, Collaborations and Agreements:
7.8 Seagen, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Research & Development Expenses
7.8.4 Recent strategies and developments:
7.8.4.1 Partnerships, Collaborations, and Agreements:
7.9 ADC Therapeutics SA
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Research & Development Expenses
7.9.4 Recent strategies and developments:
7.9.4.1 Partnerships, Collaborations, and Agreements:
7.9.4.2 Approvals and Trials:
7.10. Daiichi Sankyo Company, Limited
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Research & Development Expense
7.10.4 Recent strategies and developments:
7.10.4.1 Partnerships, Collaborations, and Agreements:
TABLE 1 Asia Pacific Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 2 Asia Pacific Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Antibody Drug Conjugates Market
TABLE 4 Acquisition & mergers – Antibody Drug Conjugates Market
TABLE 5 Approvals and trials– Antibody Drug Conjugates Market
TABLE 6 Asia Pacific Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 7 Asia Pacific Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 8 Asia Pacific Breast Cancer Market by Country, 2018 - 2021, USD Million
TABLE 9 Asia Pacific Breast Cancer Market by Country, 2022 - 2028, USD Million
TABLE 10 Asia Pacific Blood Cancer Market by Country, 2018 - 2021, USD Million
TABLE 11 Asia Pacific Blood Cancer Market by Country, 2022 - 2028, USD Million
TABLE 12 Asia Pacific Urothelial Cancer & Bladder Cancer Market by Country, 2018 - 2021, USD Million
TABLE 13 Asia Pacific Urothelial Cancer & Bladder Cancer Market by Country, 2022 - 2028, USD Million
TABLE 14 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
TABLE 15 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
TABLE 16 Asia Pacific Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 17 Asia Pacific Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 18 Asia Pacific Cleavable Linker Market by Country, 2018 - 2021, USD Million
TABLE 19 Asia Pacific Cleavable Linker Market by Country, 2022 - 2028, USD Million
TABLE 20 Asia Pacific Non-Cleavable Linker Market by Country, 2018 - 2021, USD Million
TABLE 21 Asia Pacific Non-Cleavable Linker Market by Country, 2022 - 2028, USD Million
TABLE 22 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
TABLE 23 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
TABLE 24 Asia Pacific Antibody Drug Conjugates Market by Country, 2018 - 2021, USD Million
TABLE 25 Asia Pacific Antibody Drug Conjugates Market by Country, 2022 - 2028, USD Million
TABLE 26 China Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 27 China Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 28 China Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 29 China Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 30 China Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 31 China Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 32 Japan Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 33 Japan Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 34 Japan Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 35 Japan Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 36 Japan Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 37 Japan Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 38 India Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 39 India Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 40 India Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 41 India Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 42 India Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 43 India Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 44 South Korea Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 45 South Korea Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 46 South Korea Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 47 South Korea Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 48 South Korea Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 49 South Korea Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 50 Singapore Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 51 Singapore Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 52 Singapore Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 53 Singapore Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 54 Singapore Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 55 Singapore Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 56 Malaysia Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 57 Malaysia Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 58 Malaysia Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 59 Malaysia Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 60 Malaysia Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 61 Malaysia Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 62 Rest of Asia Pacific Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 63 Rest of Asia Pacific Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 64 Rest of Asia Pacific Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 65 Rest of Asia Pacific Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 66 Rest of Asia Pacific Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 67 Rest of Asia Pacific Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million9
TABLE 68 Key Information – Takeda Pharmaceutical Company Limited
TABLE 69 KEY INFORMATION – F. HOFFMANN-LA ROCHE LTD.
TABLE 70 KEY INFORMATION – ASTRAZENECA PLC
TABLE 71 Key Information – GlaxoSmithKline PLC
TABLE 72 Key Information – Pfizer, Inc.
TABLE 73 key information – Astellas Pharma, Inc.
TABLE 74 Key Information – Gilead Sciences, Inc.
TABLE 75 Key Information – Seagen Inc.
TABLE 76 Key Information – ADC Therapeutics SA
TABLE 77 Key Information – Daiichi Sankyo Company, Limited
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2018-2022)
FIG 4 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, May – 2022, Mar) Leading Players
FIG 5 Recent strategies and developments: Takeda Pharmaceutical Company Limited
FIG 6 Recent strategies and developments: Gilead Sciences, Inc.